Established TAVR Platforms Evolving for Lifetime Management
New additions to Sapien, Evolut, Navitor lines aim to ensure coronary access
Stay updated with breaking news from Bassem Chehab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New additions to Sapien, Evolut, Navitor lines aim to ensure coronary access
The Structural Heart Team at Via Christi has successfully completed the first four cases of a new clinical trial of a new heart procedure.
Technology to be evaluated in acute decompensated heart failure patients, where current treatment options remain ineffective and lacking
Procyrion announced today that it enrolled the first patient in its investigational device exemption trial of the Aortix system.
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference News provided by Share this article Share this article IRVINE, Calif., Dec. 10, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) will discuss the company's strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance today during its annual investor conference. Highlights Presenting long-term strategic initiatives and growth outlook Projecting 2021 global sales of $4.9-5.3 billion; underlying growth in the mid-teens Projecting 2021 TAVR sales of $3.2-...